Scancell Holdings updates on clinical trial of melanoma vaccine

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma.

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma.

The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection.

The trial is being conducted in five UK centres in patients with Stage III/IV disease to assess the safety of the treatment and the immune response.

Patients are being treated with a 4.0mg dose of SCIB1, five times over six months.

Last month Scandell released findings from the first phase of the study which showed SCIB1 produced an immune response that may benefit patients with malignant melanoma.

At the same the group also announced approval from regulators to treat an extra group of patients with a higher 8.0mg dose of the vaccine.

"As expected, the recruitment of patients in the second part of the trial proceeded faster than recruitment for the first part of the trial, as we were not constrained by the cohort study design requiring sequential dose escalation, and there were more patients available with earlier stage disease," said Lindy Durrant, Joint Chief Executive Officer (CEO) of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University.

"The recruitment and dosing of the final patient in part two gives us confidence that this phase of the study will be completed by the end of 2013, consistent with previous expectations."

Shares were down 0.59% to 42.25p at 9:19 Tuesday.

RD

Recommended

The top funds to invest in
Funds

The top funds to invest in

Investors continued to the passive preference throughout May, while high-yields were also sought. We look at the top funds, stocks and trusts that inv…
5 Jun 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
20 Apr 2023
Best junior stocks and shares ISA platforms
Isas

Best junior stocks and shares ISA platforms

A junior stocks and shares ISA is a great way to save for your child tax-efficiently. But it can be confusing deciding which investment platform to ch…
28 Mar 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023

Most Popular

Saving vs investing: which is better to help you make more money?
Personal finance

Saving vs investing: which is better to help you make more money?

Saving has become a more attractive option with interest rates hitting the highest levels seen in years, but if you’re prepared to take some risk inve…
7 Jun 2023
Best debit and credit cards to use while travelling abroad
Personal finance

Best debit and credit cards to use while travelling abroad

If you’re going on holiday or travel abroad regularly, it’s worth knowing what the best card is to avoid hefty fees. We weigh up the charges and any p…
6 Jun 2023
Why is the petrol price falling, and will it rise again?
Oil

Why is the petrol price falling, and will it rise again?

Petrol prices are easing, but the broader picture is not entirely certain. Here’s what you need to know about petrol prices.
5 Jun 2023